Pulmonary vascular reserve with exercise in heart failure
- PMID: 36335982
- DOI: 10.1093/eurheartj/ehac540
Pulmonary vascular reserve with exercise in heart failure
Conflict of interest statement
Conflict of interest: B.A.B. receives research support from the National Institutes of Health (NIH) and the United States Department of Defense, as well as research grant funding from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, and Tenax Therapeutics. B.A.B. has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations, and is named inventor (US Patent no. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Other authors have no conflict of interest to declare.
Comment on
-
Pulmonary haemodynamics and pulmonary congestion: where are we now?Eur Heart J. 2022 Nov 7;43(42):4515. doi: 10.1093/eurheartj/ehac499. Eur Heart J. 2022. PMID: 36104502 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
